These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32801144)

  • 1. Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy.
    Lu X; Miao L; Gao W; Chen Z; McHugh KJ; Sun Y; Tochka Z; Tomasic S; Sadtler K; Hyacinthe A; Huang Y; Graf T; Hu Q; Sarmadi M; Langer R; Anderson DG; Jaklenec A
    Sci Transl Med; 2020 Aug; 12(556):. PubMed ID: 32801144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration.
    Li K; Wang J; Zhang R; Zhou J; Espinoza B; Niu N; Wang J; Jurcak N; Rozich N; Osipov A; Henderson M; Funes V; Lyman M; Blair AB; Herbst B; He M; Yuan J; Trafton D; Yuan C; Wichroski M; Liu X; Fu J; Zheng L
    J Hematol Oncol; 2024 Aug; 17(1):62. PubMed ID: 39113096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy.
    Muñoz NM; Williams M; Dixon K; Dupuis C; McWatters A; Avritscher R; Manrique SZ; McHugh K; Murthy R; Tam A; Naing A; Patel SP; Leach D; Hartgerink JD; Young S; Prakash P; Hwu P; Sheth RA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
    Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
    Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors.
    Xian S; Chen X; Ren S; Chen X; Wang H
    Cancer Res; 2024 Sep; 84(18):3044-3057. PubMed ID: 38990727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model.
    Marritt KL; Hildebrand KM; Hildebrand KN; Singla AK; Zemp FJ; Mahoney DJ; Jirik FR; Monument MJ
    Front Immunol; 2022; 13():1087991. PubMed ID: 36700206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
    Go EJ; Yang H; Park W; Lee SJ; Han JH; Kong SJ; Lee WS; Han DK; Chon HJ; Kim C
    Small; 2023 Oct; 19(43):e2300544. PubMed ID: 37381624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models.
    Jekle A; Thatikonda SK; Jaisinghani R; Ren S; Kinkade A; Stevens SK; Stoycheva A; Rajwanshi VK; Williams C; Deval J; Mukherjee S; Zhang Q; Chanda S; Smith DB; Blatt LM; Symons JA; Gonzalvez F; Beigelman L
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.
    Alvarez M; Molina C; De Andrea CE; Fernandez-Sendin M; Villalba M; Gonzalez-Gomariz J; Ochoa MC; Teijeira A; Glez-Vaz J; Aranda F; Sanmamed MF; Rodriguez-Ruiz ME; Fan X; Shen WH; Berraondo P; Quintero M; Melero I
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
    Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
    Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
    Xuan C; Hu R
    ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
    Corrales L; Gajewski TF
    Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered Nanovaccine Targeting Clec9a
    Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
    Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
    Shen A; Li X; Zhang Y; Ma J; Xiao R; Wang X; Song Z; Liu Z; Geng M; Zhang A; Xie Z; Ding C
    Eur J Med Chem; 2022 Nov; 241():114627. PubMed ID: 35963129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
    Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
    Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
    Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.